Abstract:Abstract Inflammasomes are multi-protein signalling scaffolds that assemble in response to invasive pathogens and sterile danger signals to activate inflammatory caspases (1/4/5/11), which trigger inflammatory death (pyroptosis) and processing and release of pro-inflammatory cytokines 1,2 . Inflammasome activation contributes to many human diseases, including inflammatory bowel disease, gout, type II diabetes, cardiovascular disease, Alzheimer’s disease, and sepsis, the often fatal response to systemic infection 3–6 . The recent identification of the pore-forming protein gasdermin D (GSDMD) as the final pyroptosis executioner downstream of inflammasome activation presents an attractive drug target for these diseases 7–11 . Here we show that disulfiram, a drug used to treat alcohol addiction 12 , and Bay 11-7082, a previously identified NF-κB inhibitor 13 , potently inhibit GSDMD pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells. Moreover, disulfiram, administered at a clinically well-tolerated dose, inhibits LPS-induced septic death and IL-1β secretion in mice. Both compounds covalently modify a conserved Cys (Cys191 in human and Cys192 in mouse GSDMD) that is critical for pore formation 8,14 . Inflammatory caspases employ Cys active sites, and many previously identified inhibitors of inflammatory mediators, including those against NLRP3 and NF-κB, covalently modify reactive cysteine residues 15 . Since NLRP3 and noncanonical inflammasome activation are amplified by cellular oxidative stress 16–22 , these redox-sensitive reactive cysteine residues may regulate inflammation endogenously, and compounds that covalently modify reactive cysteines may inhibit inflammation by acting at multiple steps. Indeed, both disulfiram and Bay 11-7082 also directly inhibit inflammatory caspases and pleiotropically suppress multiple processes in inflammation triggered by both canonical and noncanonical inflammasomes, including priming, puncta formation and caspase activation. Hence, cysteine-reactive compounds, despite their lack of specificity, may be attractive agents for reducing inflammation.

Chemical disruption of the pyroptotic pore-forming protein gasdermin D inhibits inflammatory cell death and sepsis

Gasdermin D in pyroptosis

Lipid Peroxidation Drives Gasdermin D-Mediated Pyroptosis in Lethal Polymicrobial Sepsis

Gasdermin D Open Sepsis-Induced Acute Kidney Injury Via Cell Pyroptosis by NLRP3 Inflammasome

Gasdermin D-mediated pyroptosis: mechanisms, diseases, and inhibitors

Pyroptosis inhibiting nanobodies block Gasdermin D pore formation

Identification of pyroptosis inhibitors that target a reactive cysteine in gasdermin D

The gasdermin family: emerging therapeutic targets in diseases

Ubiquitin-independent degradation of Bim blocks macrophage pyroptosis in sepsis-related tissue injury

Gasdermin D-dependent platelet pyroptosis exacerbates NET formation and inflammation in severe sepsis

FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation

Pore-forming activity and structural autoinhibition of the gasdermin family

Gasdermin D permeabilization of mitochondrial inner and outer membranes accelerates and enhances pyroptosis

Gastrodenol Suppresses NLRP3/GSDMD Mediated Pyroptosis and Ameliorates Inflammatory Diseases

Septins promote macrophage pyroptosis by regulating gasdermin D cleavage and ninjurin-1-mediated plasma membrane rupture

Pyroptosis-induced inflammation and tissue damage

New insights into Gasdermin D pore formation

Identification of a Small Molecule with Strong Anti-Inflammatory Activity in Experimental Autoimmune Encephalomyelitis and Sepsis Through Blocking Gasdermin D Activation

Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death

Gasdermin E dictates inflammatory responses by controlling the mode of neutrophil death

Gasdermin D:The killer protein performs cell pyroptosis